Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal doxorubicin + cyclophosphamide
- Development stage
- Phase 4
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
Liposomal doxorubicin + cyclophosphamide is a combination chemotherapy regimen primarily used for the treatment of metastatic breast cancer and other solid tumors. Liposomal doxorubicin is an anthracycline antibiotic encapsulated in liposomes, which helps reduce cardiotoxicity and prolongs circulation time compared to conventional doxorubicin. It works by intercalating into DNA and inhibiting topoisomerase II, leading to DNA damage, inhibition of cell proliferation, and induction of apoptosis[5][6]. Cyclophosphamide is an alkylating agent that interferes with the growth of cancer cells by cross-linking DNA strands, resulting in cell death[7]. This combination has demonstrated efficacy as first-line therapy for metastatic breast cancer with a favorable safety profile compared to standard regimens[1][2].
- Brand names
- MyocetCaelyx
- Other names
- pegylated liposomal doxorubicin
02
Targets
DNAN7-G (DNA guanine-N7 adduct)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on liposomal doxorubicin + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal doxorubicin + cyclophosphamide.